Top

Published in:

01-04-2012 | Research Article

DNA methylation biomarker candidates for early detection of colon cancer

Authors: Joo Mi Yi, Mashaal Dhir, Angela A. Guzzetta, Christine A. Iacobuzio-Donahue, Kyu Heo, Kwang Mo Yang, Hiromu Suzuki, Minoru Toyota, Hwan-Mook Kim, Nita Ahuja

Published in: Tumor Biology | Issue 2/2012

Abstract

Promoter CpG island hypermethylation of tumor suppressor genes is a common hallmark of all human cancers. Many researchers have been looking for potential epigenetic therapeutic targets in cancer using gene expression profiling with DNA microarray approaches. Our recent genome-wide platform of CpG island hypermethylation and gene expression in colorectal cancer (CRC) cell lines revealed that FBN2 and TCERG1L gene silencing is associated with DNA hypermethylation of a CpG island in the promoter region. In this study, promoter DNA hypermethylation of FBN2 and TCERG1L in CRC occurs as an early and cancer-specific event in colorectal cancer. Both genes showed high frequency of methylation in colon cancer cell lines (>80% for both of genes), adenomas (77% for FBN2, 90% for TCERG1L, n = 39), and carcinomas (86% for FBN2, 99% for TCERG1L, n = 124). Bisulfite sequencing confirmed cancer-specific methylation of FBN2 and TCERG1L of promoters in colon cancer cell line and cancers but not in normal colon. Methylation of FBN2 and TCERG1L is accompanied by downregulation in cell lines and in primary tumors as described in the Oncomine™ website. Together, our results suggest that gene silencing of FBN2 and TCERG1L is associated with promoter DNA hypermethylation in CRC tumors and may be excellent biomarkers for the early detection of CRC.

Jemal ASR, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRef

Heresbach DMS, D'halluin PN, Bretagne JF, Branger B. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol. 2006;18:427–33.PubMedCrossRef

Meissner HI, Breen N, Klabunde CN, Vernon SW. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers & Prevention. 2006;15:389–94.CrossRef

Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–54.PubMedCrossRef

Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–92.PubMedCrossRef

Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Dong Chen W, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004;36:417–22.PubMedCrossRef

Akiyama Y, Watkins N, Suzuki H, Jair KW, van Engeland M, Esteller M, et al. Gata-4 and gata-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol. 2003;23:8429–39.PubMedCrossRef

Glockner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, et al. Methylation of tfpi2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 2009;69:4691–9.PubMedCrossRef

Schuebel KE, Chen W, Cope L, Glöckner SC, Suzuki H, Yi JM, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genetics. 2007;3:1709–23.PubMedCrossRef

10.

Karpf AR JD. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Oncogene. 2002;21:5496–503.PubMedCrossRef

11.

Yang Q, Ota K, Tian Y, Kumar A, Wada J, Kashihara N, et al. Cloning of rat fibrillin-2 cDNA and its role in branching morphogenesis of embryonic lung. Dev Biol. 1999;212:229–42.PubMedCrossRef

12.

Hagihara A, Miyamoto K, Furuta J, Hiraoka N, Wakazono K, Seki S, et al. Identification of 27 5′ CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene. 2004;23:8705–10.PubMedCrossRef

13.

Sune C, Hayashi T, Liu Y, Lane WS, Young RA, Garcia-Blanco MA. Ca150, a nuclear protein associated with the RNA polymerase ii holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription. Mol Cell Biol. 1997;17:6029–39.PubMed

14.

Sanchez-Alvarez M, Goldstrohm AC, Garcia-Blanco MA, Sune C. Human transcription elongation factor ca150 localizes to splicing factor-rich nuclear speckles and assembles transcription and splicing components into complexes through its amino and carboxyl regions. Mol Cell Biol. 2006;26:4998–5014.PubMedCrossRef

15.

Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, et al. DNMT1 and DNMT3B cooperate to silence genes in human cancer cells. Nature. 2002;416:552–6.PubMedCrossRef

16.

Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821–6.PubMedCrossRef

17.

Rhodes DR YJ, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, et al. Oncomine: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6:1–6.PubMed

18.

Kaiser SPY, Franklin JL, Halberg RB, Yu M, Jessen WJ, Freudenberg J, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol. 2007;8:R131.PubMedCrossRef

19.

Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, et al. Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage b and c colorectal cancer. Clin Cancer Res. 2009;15:7642–51.PubMedCrossRef

20.

Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010;138:958–68.PubMedCrossRef

21.

Watanabe T, Kobunai T, Toda E, Yamamoto Y, Kanazawa T, Kazama Y, et al. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res. 2006;66:9804–8.PubMedCrossRef

22.

Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457–63.PubMedCrossRef

23.

Chan TA GS, Yi JM, Chen W, Van Neste L, Cope L, Herman JG, et al. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med. 2008;5:0823–38.

24.

Yi JM, Dhir M, Van Neste L, Downing SR, Jeschke J, Glockner SC, et al. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res. 2011;17:1535–45.PubMedCrossRef

25.

Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007;16:R50–9.PubMedCrossRef

26.

Zhang W, Glockner SC, Guo M, Machida EO, Wang DH, Easwaran H, et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Research. 2008;68:2764–72.PubMedCrossRef

27.

Tsunoda SSE, De Young NJ, Wang X, Tian ZQ, Liu JF, Jamieson GG, et al. Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma. Oncological Report. 2009;21:1067–73.

28.

Cortese R, Hartmann O, Berlin K, Eckhardt F. Correlative gene expression and DNA methylation profiling in lung development nominate new biomarkers in lung cancer. Int J Biochem Cell Biol. 2008;40:1494–508.PubMedCrossRef

29.

Chen H, Suzuki M, Nakamura Y, Ohira M, Ando S, Iida T, et al. Aberrant methylation of FBN2 in human non-small cell lung cancer. Lung Cancer. 2005;50:43–9.PubMedCrossRef

30.

Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3:253–66.PubMedCrossRef

31.

Lofton-Day C, Model F, DeVos T, Tetzner R, Distler J, Schuster M, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem. 2008;54:414–23.PubMedCrossRef

32.

Kim MS LJ, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Review. 2010;29:181–206.CrossRef

33.

Melotte VLM, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, Daenen KL, et al. N-Myc downstream-regulated gene 4 (NDGR4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Canc Inst. 2009;101:916–27.CrossRef

34.

Melotte V, Lentjes MHFM, van den Bosch SM, Hellebrekers DMEI, de Hoon JPJ, Wouters KAD, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J National Cancer Institute. 2009;101:916–27.CrossRef

Title: DNA methylation biomarker candidates for early detection of colon cancer
Authors: Joo Mi Yi
Mashaal Dhir
Angela A. Guzzetta
Christine A. Iacobuzio-Donahue
Kyu Heo
Kwang Mo Yang
Hiromu Suzuki
Minoru Toyota
Hwan-Mook Kim
Nita Ahuja
Publication date: 01-04-2012
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 2/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-011-0302-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Optimized labeling of NOTA-conjugated octreotide with F-18

Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma

Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer

Emerging links between epigenetic alterations and dysregulation of noncoding RNAs in cancer

A lipoprotein source of cholesteryl esters is essential for proliferation of CEM-CCRF lymphoblastic cell line

Cellular changes in the tumor microenvironment of human esophageal squamous cell carcinomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer